News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ViaCell, Inc. (VIAC) Announces Its Initial Public Offering



10/19/2005 5:12:31 PM

BOSTON, Jan. 21 /PRNewswire-FirstCall/ -- ViaCell, Inc. today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a price of $7.00 per share. All of the shares are being offered by ViaCell. In addition, ViaCell has granted to the underwriters a 30- day option to purchase up to an additional 1,125,000 shares of common stock to cover over-allotments, if any. ViaCell's common stock is expected to begin trading on The NASDAQ National Market on January 21, 2005 under the symbol "VIAC."

Credit Suisse First Boston and UBS Investment Bank are acting as joint book-running managers, and Lazard and Leerink Swann & Company are acting as co-managers for this offering.

Copies of the final prospectus relating to this offering may be obtained, when available, from Credit Suisse First Boston LLC, Prospectus Department, One Madison Avenue, Level 1B, New York, NY 10010 (telephone number: 212-325- 2580); or UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171 (telephone number: 212-821-3000).

ViaCell, Inc. is a clinical-stage biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company is developing a pipeline of proprietary product candidates intended to address cancer, cardiac diseases and infertility. ViaCell's portfolio of proprietary technologies include Selective Amplification technology and USSC. The Company's lead stem cell therapy product candidate, a cord blood-derived stem cell therapeutic, CB001, is currently in a Phase I clinical trial. ViaCell offers expecting families the option of preserving their baby's cord blood stem cells through its Viacord business.

A registration statement relating to the common stock has been filed with and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

ViaCell, Inc.

CONTACT: Corporate Contact - Marc Beer of ViaCell, Inc., 1-800-766-0966,mbeer@viacellinc.com; or Media Contact-US - Justin Jackson of Burns McCllelan,+1-212-213-0006, jjackson@burnsmc.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES